We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Prospective Study of Warfarin Dosage Requirements Based on CYP2C9 and VKORC1 Genotypes.
- Authors
Wen, M.-S.; Lee, M. T. M.; Chen, J.-J.; Chuang, H.-P.; Lu, L.-S.; Chen, C.-H.; Lee, T.-H.; Kuo, C.-T.; Sun, F.-M.; Chang, Y.-J.; Kuan, P.-L.; Chen, Y.-F.; Charng, M.-J.; Ray, C.-Y.; Wu, J.-Y.; Chen, Y.-T.
- Abstract
Polymorphisms in CYP2C9 and VKORC1 have been shown to be associated with warfarin dose requirements and could be used to predict warfarin dose. We conducted a prospective study in which warfarin dose was prescribed based on CYP2C9 and VKORC1 polymorphisms in 108 Han-Chinese patients without prior warfarin treatments. Using the genotype-based dosing, 83% of patients reached stable, therapeutic international normalized ratio (INR) within 2 weeks of treatment initiation and none of the patients developed clinical bleeding or thromboembolic event. Ten percent (11) of patients with INR >4 and no clinical bleeding were detected during this study. At 12 weeks, 69% of the patients' maintenance doses matched the prediction. Dosing algorithms incorporating genetic factors, age, and body surface area were developed, which could explain up to 62% of the total variation (R2 of 0.62). This study demonstrated that pharmacogenetics-based dosing could improve time to stable, therapeutic INR, reduce adverse events, and achieve high sensitivity.Clinical Pharmacology & Therapeutics (2008); 84, 1, 83–89 doi:10.1038/sj.clpt.6100453
- Subjects
WARFARIN; ANTICOAGULANTS; PHARMACOGENOMICS; GENETIC polymorphisms; CHINESE people; CLINICAL pharmacology
- Publication
Clinical Pharmacology & Therapeutics, 2008, Vol 84, Issue 1, p83
- ISSN
0009-9236
- Publication type
Article
- DOI
10.1038/sj.clpt.6100453